Literature DB >> 25548486

Differential gene expression profiling of gastric intraepithelial neoplasia and early-stage adenocarcinoma.

Xue Xu1, Lin Feng1, Yu Liu1, Wei-Xun Zhou1, Ying-Cai Ma1, Gui-Jun Fei1, Ning An1, Yuan Li1, Xi Wu1, Fang Yao1, Shu-Jun Cheng1, Xing-Hua Lu1.   

Abstract

AIM: To investigate the differentiated whole genome expression profiling of gastric high- and low-grade intraepithelial neoplasia and early-stage adenocarcinoma.
METHODS: Gastric specimens from an upper magnifying chromoendoscopic targeted biopsy were collected from March 2010 to May 2013. Whole genome expression profiling was performed on 19 low-grade intraepithelial neoplasia (LGIN), 20 high-grade intraepithelial neoplasia (HGIN), 19 early-stage adenocarcinoma (EGC), and 19 chronic gastritis tissue samples using Agilent 4 × 44K Whole Human Genome microarrays. Differentially expressed genes between different types of lesions were identified using an unpaired t-test and corrected with the Benjamini and Hochberg false discovery rate algorithm. A gene ontology (GO) enrichment analysis was performed using the GeneSpring software GX 12.6. The differentially expressed gene was verified using a real-time TaqMan® PCR assay with independent tissue samples, including 26 LGIN, 15 HGIN, 14 EGC, and 20 chronic gastritis. The expression of G0S2 were further validated by immunohistochemical staining (IHC) in 24 LGIN, 40 HGIN, 30 EGC and 61 chronic gastritis specimens.
RESULTS: The gene expression patterns of LGIN and HGIN tissues were distinct. There were 2521 significantly differentially expressed transcripts in HGIN, with 951 upregulated and 1570 downregulated. A GO enrichment analysis demonstrated that the most striking overexpressed transcripts in HGIN compared with LGIN were in the category of metabolism, defense response, and nuclear factor κB (NF-κB) cascade. While the vast majority of transcripts had barely altered expression in HGIN and EGC tissues, only 38 transcripts were upregulated in EGC. A GO enrichment analysis revealed that the alterations of the immune response were most prominent in the progression from HGIN to EGC. It is worth noting that, compared with LGIN, 289 transcripts were expressed at higher levels both in HGIN and EGC. A characteristic gene, G0/G1 switch 2 (G0S2) was one of the 289 transcripts and related to metabolism, the immune response, and the NF-κB cascade, and its expression was validated in independent samples through real-time TaqMan® PCR and immunohistochemical staining. In real-time PCR analysis, the expression of G0S2 was elevated both in HGIN and EGC compared with that in LGIN (P < 0.01 and P < 0.001, respectively). In IHC analysis, G0S2 immunoreactivity was detected in the cytoplasmic of neoplastic cells, but was undetectable in chronic gastritis cells. The G0S2 expression in HGIN was higher than that of LGIN (P = 0.012, χ (2) = 6.28) and EGC (P = 0.008, χ (2) = 6.94).
CONCLUSION: A clear biological distinction between gastric high- and low-grade intraepithelial neoplasia was identified, and provides molecular evidence for clinical application.

Entities:  

Keywords:  G0/G1 switch 2; Gastric early-stage adenocarcinoma; High-and low-grade intraepithelial neoplasia; Immunohistochemical staining; Quantitative real-time PCR; Whole genome expression microarray

Mesh:

Substances:

Year:  2014        PMID: 25548486      PMCID: PMC4273138          DOI: 10.3748/wjg.v20.i47.17883

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

3.  Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells.

Authors:  N Takahashi; T Okumura; W Motomura; Y Fujimoto; I Kawabata; Y Kohgo
Journal:  FEBS Lett       Date:  1999-07-16       Impact factor: 4.124

Review 4.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

Review 5.  Gastric precancerous changes: carcinogenesis, clinical behaviour immunophenotype study and surveillance.

Authors:  G Testino
Journal:  Panminerva Med       Date:  2006-06       Impact factor: 5.197

6.  Gastrointestinal epithelial neoplasia: Vienna revisited.

Authors:  M F Dixon
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 7.  NF-kappaB and cancer-identifying targets and mechanisms.

Authors:  Willscott E Naugler; Michael Karin
Journal:  Curr Opin Genet Dev       Date:  2008-04-24       Impact factor: 5.578

Review 8.  IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.

Authors:  Julia Bollrath; Florian R Greten
Journal:  EMBO Rep       Date:  2009-11-06       Impact factor: 8.807

9.  Adipose triglyceride lipase contributes to cancer-associated cachexia.

Authors:  Suman K Das; Sandra Eder; Silvia Schauer; Clemens Diwoky; Hannes Temmel; Barbara Guertl; Gregor Gorkiewicz; Kuppusamy P Tamilarasan; Pooja Kumari; Michael Trauner; Robert Zimmermann; Paul Vesely; Guenter Haemmerle; Rudolf Zechner; Gerald Hoefler
Journal:  Science       Date:  2011-06-16       Impact factor: 47.728

10.  Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2.

Authors:  Christian Welch; Manas K Santra; Wissal El-Assaad; Xiaochun Zhu; Wade E Huber; Richard A Keys; Jose G Teodoro; Michael R Green
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

View more
  8 in total

1.  A Single-Center Follow-Up Study of Low-Grade Gastric Intraepithelial Neoplasia and the Screening of Key Genes of Precancerous Lesions.

Authors:  Xiao-Xu Jin; Xiao-Li Xie; Fu Niu; Kai-Ge Yin; Chen-Guang Ji; Jin-Feng Cui; Li Liu; Zhi-Jie Feng
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

2.  Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.

Authors:  Jian Li; Yao Zhang; Dengmin Hu; Tuping Gong; Run Xu; Jun Gao
Journal:  Aging (Albany NY)       Date:  2020-07-15       Impact factor: 5.682

3.  ICAM1 Regulates the Development of Gastric Cancer and May Be a Potential Biomarker for the Early Diagnosis and Prognosis of Gastric Cancer.

Authors:  Songda Chen; Shan Pan; Huijie Wu; Jingyuan Zhou; Yueli Huang; Shuai Wang; Aiqun Liu
Journal:  Cancer Manag Res       Date:  2020-03-02       Impact factor: 3.989

4.  Expression of Oncostatin M in Early Gastric Cancer and Precancerous Lesions.

Authors:  Jihua Shi; Xue Xu; Jun Du; Haimeng Cui; Qingfeng Luo
Journal:  Gastroenterol Res Pract       Date:  2019-12-01       Impact factor: 2.260

5.  Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.

Authors:  Fan Zhang; Ewetse Paul Maswikiti; Yucai Wei; Wenzhang Wu; Yumin Li
Journal:  Dis Markers       Date:  2021-08-12       Impact factor: 3.434

6.  Manpixiao Decoction Halted the Malignant Transformation of Precancerous Lesions of Gastric Cancer: From Network Prediction to In-Vivo Verification.

Authors:  Yuan Li; Tao Li; Jiena Chen; Haocheng Zheng; Yicong Li; Fuhao Chu; Sici Wang; Ping Li; Jie Lin; Zeqi Su; Xia Ding
Journal:  Front Pharmacol       Date:  2022-08-05       Impact factor: 5.988

7.  Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types.

Authors:  Jaeik Oh; Chanwoong Hwa; Dongjun Jang; Seungjae Shin; Soo-Jin Lee; Jiwon Kim; Sang Eun Lee; Hae Rim Jung; Yumi Oh; Giyong Jang; Obin Kwon; Joon-Yong An; Sung-Yup Cho
Journal:  Exp Mol Med       Date:  2022-07-06       Impact factor: 12.153

Review 8.  HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach.

Authors:  A Ieni; V Barresi; L Rigoli; R A Caruso; G Tuccari
Journal:  Dis Markers       Date:  2015-10-01       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.